Search Results 1511-1520 of 20788 for Informed consent

1. Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 - Mayo Clinic

   Age at time of signing the informed consent/assent form: Cohorts 1-3: ≥ 18 years to ≤ 64 years; Cohort 4: ≥ 6 years to < 18 years (Note: the first ...

2. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

   ... informed consent. History of another primary malignancy except for the following: Prostate cancer of pathologic stage less than or equal to T2cN0M0 ...

3. A Study Of Treatment For Medulloblastoma Using Sodium Thiosulfate To Reduce Hearing Loss - Mayo Clinic

   ... informed consent for APEC14B1 Part A - Eligibility Screening and consent for the Molecular Characterization Initiative (MCI). PRE-ENROLLMENT: The required ...

4. An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... informed consent through 90 days after the last dose of study therapy; OR; Agree to practice true abstinence, when this is in line with the preferred and ...

5. Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... informed consent through 90 days after the last dose of study drug, or; agree ... consent may be withdrawn by the participant at any time without ...

6. Study to Evaluate the Effectiveness and Safety of Remdesivir in Participants with Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 - Mayo Clinic

   Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under ICH E6(R2) 4.8.15 ...

7. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

   * Must sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing ...

8. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   Signed written informed consent; · Histologically or cytologically confirmed non-small cell cancer of the lung (NSCLC) stage IV (accordingto AJCC Staging 7th ...

9. Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant - Mayo Clinic

   Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial ...

10. A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) - Mayo Clinic

    Provision of signed and dated informed consent form for the randomized trial by patient and/or legal guardian. 2. Age ≤25 years old at time of randomized ...